After introducing Expressive Captions in December, the Live Caption panel on Pixel devices now offers a Background ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for Alzheimer’s disease, providing a response after a meeting next month.
Eisai and Biogen update on lecanemab's EU regulatory review for early Alzheimer’s disease treatment following positive CHMP opinion. Eisai Co., Ltd. and Biogen Inc. have provided an update on ...
Eisai and Biogen scored an approval for once-monthly IV maintenance dosing of their Alzheimer’s drug Leqembi, as part of what they’ve said is an ongoing … ...
Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab-irmb) has been approved by the US Food and Drug Administration (FDA) for monthly maintenance dosing. The anti-amyloid drug was ...
Credit: Chinnapong/Shutterstock. The US Food and Drug Administration has approved the supplemental biologics licence application (sBLA) of Eisai and Biogen’s Leqembi (lecanemab-irmb) for maintenance ...
Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) have secured US Food and Drug Administration approval for a once-monthly intravenous maintenance dosing regimen for Leqembi (lecanemab). Already approved ...
Additionally, a monthly dosing schedule for Leqembi “may be easier for patients and care partners to continue treatment,” potentially helping with the drug’s uptake, according to Eisai’s press ...
(Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on Monday. The drug ...
Jan 27 (Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai (4523.T), opens new tab and partner Biogen's (BIIB.O), opens new tab Alzheimer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback